Close menu

December 30th, 2022 | 17:52 CET

BioNTech, Defence Therapeutics, Pfizer - The cards are being reshuffled

  • Biotechnology
  • Covid19
  • Investments
Photo credits:

The Corona pandemic is seemingly coming to an end after almost three long years. The return to normality, now in China and the rest of the world, is a relief for society and the economy. In contrast, vaccine manufacturers are losing a billion-dollar business that is difficult to compensate for with products in other areas of application. Nevertheless, the stock market valuations of the vaccine producers continue to be exorbitantly high, as does their drop in value.

time to read: 4 minutes | Author: Stefan Feulner

Table of contents:

    Single-product company seeks alternatives

    The abrupt end of the "Zero-COVID policy" in China caused a sigh of relief around the globe last week. The return to normality should now be set. Even the well-known and previously very cautious virologist Christian Drosten considers the Corona pandemic in Germany to be over. This winter was the first endemic wave, he told "Tagesspiegel". Justice Minister Bushman also calls for the end of all Corona measures as a consequence.

    The announcement of the end of the pandemic is likely to have put global vaccine manufacturers on high alert, especially if, as is the case with BioNTech, the Corona vaccines are the only products marketable to date, which, looking at the product pipeline, is unlikely to change in the near future. Although the Mainz-based company repeatedly emphasizes that it is driving forward the field of oncology based on mRNA technology, experience has shown that it will probably be years before actual approval is granted.

    In addition, BioNTech and its US partner Pfizer have developed a combination vaccine that could be used in the future to vaccinate against Corona and influenza at the same time. This has been included in an accelerated approval process by the US Food and Drug Administration (FDA). Whether this vaccine will be well received once approved is questionable. Currently, BioNTech's market capitalization is USD 36.82 billion, despite correction. As of September 30, 2022, the Company had high liquidity of EUR 13.4 billion and trade receivables of EUR 7.3 billion. For the full year 2022, the Mainz-based company still expects between EUR 16 and 17 billion in sales. For 2023, the decline in sales and earnings is likely to be drastic, should the Corona pandemic be over.

    From a chart perspective, the situation does not look any better. After bouncing off the high for the year at USD 188.82, the share fell back into its broad sideways channel with high volumes, which marks the low for the year at USD 117.48 as the lower edge. RSI and MACD gave a fresh sell signal on a weekly basis, so a further slide into this region or below appears likely.

    Completely new possibilities against cancer

    Compared to BioNTech, the Canadian biotech company Defence Therapeutics, with a market capitalization of USD 69.71 million, is far from exaggerated. That is because the Canadians' highly scalable platform technology has the potential to develop the next generation of vaccines and ADC products. At the core of the Defence Therapeutics platform is ACCUM technology, which enables the precise transport of vaccine antigens or ADCs in the intact form to target cells. As a result, improved efficiency and efficacy against serious diseases such as cancer and infectious diseases can be achieved.

    Currently, Defence Therapeutics is working on combining its ACCUM technology with mRNA vaccines. This research program will not only impact the field of cancer immunotherapy but can also be directly applied to developing new vaccines against infectious diseases. For example, the Canadians have demonstrated that while "pure" mRNA can indeed be immunogenic, the humoral antibody response generated against the vaccine is very weak. The Defence team is therefore working with a private European company to synthesize mRNA vaccines in conjunction with ACCUM. The goal is to directly compare ACCUM-linked and "pure" mRNA vaccines in terms of their potential to generate an immune response that can eradicate and control existing tumors. According to Defence Therapeutics CEO Sebastien Plouffe, the ACCUM mRNA vaccine is expected to be in production by the end of 2023. After that, in vivo studies will be initiated in animals with existing solid tumors. "Once completed, Defence will have its 100% proprietary ACCUM-linked cancer mRNA vaccine. Defence will also be able to license its customized ACCUM technology to any pharmaceutical company with mRNA vaccines," he added.

    Groundbreaking results

    Also groundbreaking were the results of a preclinical study using the intranasal formulation of AccuTOX in the context of animals with existing lung cancer. The study showed that administration of AccuTOX as a combination therapy with the immune checkpoint inhibitor PD-1 antibody dramatically reduced the number of lung nodules compared to animals in the untreated or PD-1 antibody-treated control group. This 50% reduction in cancer nodules in animals with existing lung tumors was achieved with a treatment schedule of just 6 doses administered over a 2-week period with the combination of AccuTOX and PD-1 antibodies. Defence is currently preparing its meeting with the US Food and Drug Administration (FDA) to seek approval to initiate a Phase I trial for the treatment against solid tumors in 2023. According to Precedence Research, the global lung cancer therapeutics market was valued at approximately USD 27.57 billion in 2021 and is expected to grow to USD 55.6 billion by 2030.

    The Corona pandemic is coming to an end in leaps and bounds, which means an end to the special boom for vaccine manufacturers like BioNTech. With only one product established in the market, the Company's forecasts for 2023 are likely to be somewhat sobering. In comparison, Defence Therapeutics has enormous growth potential with its highly scalable platform technology.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by Juliane Zielonka on June 1st, 2023 | 09:30 CEST

    BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns

    • Biotechnology
    • Pharma
    • AI

    Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.


    Commented by Fabian Lorenz on June 1st, 2023 | 08:45 CEST

    JinkoSolar, BioNTech and First Phosphate with important updates: This is what moves the shares

    • Mining
    • phosphate
    • photovoltaics
    • Biotechnology

    The energy transition is moving forward. In Germany, the traffic light government seems to have agreed on a new heating law. In the US, the agreement between Democrats and Republicans on the debt ceiling is a good sign for the industry because the promotion of environmentally friendly technologies depends on it. JinkoSolar and First Phosphate, among others, should benefit from this. Both companies have published important updates. There is also important news at BioNTech. However, these are not so positive. When will there be new impulses for the share?


    Commented by André Will-Laudien on May 31st, 2023 | 08:30 CEST

    Biotech in turnaround mode! BioNTech, Defence Therapeutics, MorphoSys, Formycon - Take a close look at these shares!

    • Biotechnology
    • Pharma
    • vaccine

    Since the major pandemic wave in the biotech sector, most industry players have had to come to terms with normality again. Scolded investors quickly learned their lesson and are now looking warily at an industry that experienced its heyday between 2019 and 2021. Today, it is no longer the small announcements of hope that lead to significant price swings. After months of sell-offs, however, the sector is stabilizing for the first time, and some protagonists can report minor progress. When the sector trend weakens, selection is the trump card. Here are some suggestions.